PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma - Related Studies

PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

This study has been completed.

Study NCT00048230. Last updated on July 12, 2007. Information provided by Millennium Pharmaceuticals

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Multiple Myeloma

2	Additional conditions recognized in this trial
		Neoplasms, Plasma Cell

3	More general conditions related to this trial
		Blood Protein Disorders
		Cardiovascular Diseases
		Hematologic Diseases
		Hemorrhagic Disorders
		Hemostatic Disorders
		Immune System Diseases
		Immunoproliferative Disorders
		Lymphoproliferative Disorders
		Neoplasms
		Neoplasms by Histologic Type
		Paraproteinemias
		Vascular Diseases

4	Interventions listed in this trial
		bortezomib

5	Additional drug interventions recognized in this trial
		Dexamethasone

6	More general drug interventions related to this trial
		Anti-Inflammatory Agents
		Antiemetics
		Antineoplastic Agents
		Antineoplastic Agents, Hormonal
		Autonomic Agents
		Central Nervous System Agents
		Enzyme Inhibitors
		Gastrointestinal Agents
		Glucocorticoids
		Hormones
		Hormones, Hormone Substitutes, and Hormone Antagonists
		Molecular Mechanisms of Pharmacological Action
		Peripheral Nervous System Agents
		Pharmacologic Actions
		Physiological Effects of Drugs
		Protease Inhibitors
		Therapeutic Uses

7	Sponsors listed in this trial
		Millennium Pharmaceuticals